The DOI matches its Crossref record; 60 of the 67 references it cites were found in a registry or an index; 12 of the 35 sources its claims cite were checked for support.
Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
Open accessAbstract
To perform a systematic review and meta-analysis to evaluate the effectiveness and safety of probiotics in the treatment of constipation-predominant irritable bowel syndrome (IBS-C), we searched for randomized controlled trials (RCTs) comparing probiotic care versus placebos for patients with IBS-C in five comprehensive databases (March 2022). The risk of bias was assessed using the Cochrane Collaboration Risk of Bias Tool. RevMan 5.3 was used to perform a meta-analysis on stool consistency, abdominal pain, bloating, quality of life (QoL), fecal Bifidobacterium and Lactobacillus counts, and adverse events. The GRADE approach was used to evaluate the certainty of the evidence. Ten RCTs involving 757 patients were included. Only three studies were rated as having a low risk of bias. The meta-analysis results show that, compared to the placebo, probiotics significantly improved stool consistency (MD = 0.72, 95% CI (0.18, 1.26), p < 0.05, low quality) and increased the number of fecal Bifidobacteria (MD = 1.75, 95% CI (1.51, 2.00), p < 0.05, low quality) and Lactobacillus (MD = 1.69, 95% CI (1.48, 1.89), p < 0.05, low quality), while no significant differences were found in abdominal pain scores, bloating scores, QoL scores, or the incidence of adverse events (p > 0.05). The low-to-very low certainty evidence suggests that probiotics might improve the stool consistency of patients with IBS-C and increase the number of Bifidobacteria and Lactobacilli in feces with good safety. However, more high-quality studies with large samples are needed to verify the findings.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 10 RCTs (757 IBS-C patients) found that probiotics improved stool consistency and increased fecal Bifidobacteria and Lactobacilli versus placebo, with no significant overall effects on abdominal pain, bloating, QoL, or adverse events. Evidence certainty was low to very low, so the authors conclude probiotics may be beneficial and safe but that larger, higher-quality trials are needed.
Key findings
- Probiotics significantly improved stool consistency versus placebo (MD = 0.72, 95% CI 0.18–1.26, p < 0.05; low quality) and increased fecal Bifidobacteria (MD = 1.75, 95% CI 1.51–2.00, p < 0.05; low quality) and Lactobacillus (MD = 1.69, 95% CI 1.48–1.89, p < 0.05; low quality).
- No significant overall differences were found for abdominal pain (SMD = −0.28, 95% CI −0.60–0.05, p > 0.05), bloating (SMD = −0.14, 95% CI −0.46–0.18, p > 0.05), QoL (SMD = −3.92, 95% CI −8.09–0.25, p > 0.05), or adverse events (OR = 1.57, 95% CI 0.87–2.82, p > 0.05).
- Sensitivity analyses for abdominal pain, bloating, and QoL were unstable; after excluding one study, abdominal pain became significant (SMD = −0.20, 95% CI −0.38 to −0.01, p < 0.05, I² = 0%) and bloating became significant (SMD = −0.31, 95% CI −0.61 to −0.02, p < 0.05).
- GRADE certainty was low for abdominal pain, bloating, stool consistency, adverse events, and fecal Bifidobacteria/Lactobacilli, and very low for QoL.
Methods
- Systematic review and meta-analysis of randomized controlled trials comparing probiotics versus placebo in patients with IBS-C diagnosed by Rome I–IV criteria; primary outcomes were stool consistency and fecal colony counts, with secondary outcomes of abdominal pain, bloating, QoL, and adverse events.
- Five databases (PubMed, Embase, Cochrane Library, Web of Science, CBM) were searched from inception to March 2021, updated March 2022; 10 RCTs with 757 patients were included.
- RevMan 5.3 was used for meta-analysis with MD, SMD, or OR and 95% CIs; heterogeneity was assessed with χ² and I², and the Cochrane Risk of Bias Tool and GRADE were used for quality and certainty assessment.
Limitations
- The authors state that only English-language reports were covered, which may have led to language bias; results are based only on currently published literature; and most studies reported multiple probiotic mixtures, so specific strains could not be analyzed.
- The paper reports that only 3 of 10 RCTs were rated low risk of bias, while 7 were unclear, mainly due to incomplete reporting of random sequence generation, allocation concealment, and blinding.
- The text makes evident additional limitations: small sample sizes, statistical heterogeneity in abdominal pain, QoL, and bloating, unstable sensitivity analyses, and no publication bias detection because all outcomes had fewer than 10 studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Risk of bias assessment for the included studies [49,50,51,52,53,54,55,56,57,58].](https://figures.cochat.ai/paper-figures/bc88ce1c7e644bf3bcbacce58653fdff/effectiveness-and-safety-of-probiotics-for-patients-with-constipation-figure-2.jpg)






Verification
Claims the paper makes
7 Valid · 0 Not valid · 7 Not checked · 83 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A questionnaire survey was conducted on 94 patients with IBS, and only 12/94 (12.8%) were satisfied with the treatment they had been given [20,21].”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [20] Ford, 2009, Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis, Gut source
- Supportedcites [21] Olafsdottir, 2012, Irritable bowel syndrome: Physicians’ awareness and patients’ experience, World J. Gastroenterol. source
The Patient study section (p. of our copy) states verbatim that 'A total of 94 patients underwent telephone interview' and 'Only 12/94 (12.8%) IBS patients were satisfied with the treatment they had been given', and Table 2 lists 'Satisfied with treatment for IBS 12 (12.8)' among all patients (n = 94). The survey instrument for the 94 patients is described as a telephone interview (with the mailed questionnaire used to identify/recruit them), so 'questionnaire survey' is a slightly loose label but the attributed content — 94 IBS patients, 12/94 (12.8%) satisfied — is exactly what our copy reports. The separate 57.9% satisfaction figure refers only to the subset who received management for their symptoms, not to the whole cohort, so it does not contradict the claim. (LLM, conf=0.90)
plainn = 94- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The failure of existing treatment options to adequately control the symptoms of IBS-C has been shown to result in increased treatment costs and healthcare resource use [22].”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 1. Introduction
What the sources say
- Partly supportedcites [22] Guerin, 2014, The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: A retrospective analysis of a Medicaid population, J. Med. Econ. sourceExperimental — accuracy not yet measured
Our copy supports the substance: the Healthcare resource utilization and costs section (p. 8) reports significantly higher rates of all HRU and higher total costs in the IBS-C treatment-failure cohort ($18,886 vs $13,897; adjusted incremental $4353), and the Abstract (p. 5) concludes sub-optimal treatment response 'may lead to substantial HRU and healthcare costs.' However, the citing sentence states this as a demonstrated causal result ('has been shown to result in'), whereas the Limitations section states 'the HRU and costs data reported may not be causally related to unmet needs and treatment failure' and that the study 'can, therefore, establish only a temporal association.' Also, the incremental cost attributed to 'treatment costs' is largely not IBS-C treatment cost: the Results (p. 7) note constipation/IBS-C treatment costs contributed only 2% of the IBS-C incremental cost, with medical service, pharmacy and inpatient costs driving it. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study intervened with a mixture of two probiotics at the same dose, which could lead to bias that affected the evidence for the results [53].”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 4. Discussion > 4.1. Summary of the Main Results
What the sources say
- Partly supportedcites [53] Mezzasalma, V., Manfrini, E., Ferri, E., Sandionigi, A., La Ferla, B., Schiano, I., Michelotti, A., Nobile, V., Labra, M., and Di Gennaro, P. (2016). A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. BioMed Res. Int., 2016. sourceExperimental — accuracy not yet measured
The Introduction describes F1 as a mixture of two probiotic species, and Study Design (§2.1; page not available) says participants received one capsule daily. The paper does not establish that the probiotic species were given at the same dose or say that the mixture introduced bias affecting the results. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four RCTs [50,54,57,58] reported 54 patients with adverse events, including abdominal pain, anal irritation, gastroesophageal reflux, constipation, and cramping.”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 3. Results > 3.4. Meta-Analysis
plainn = 54- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only three studies were rated as having a low risk of bias.”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims
Create a free account to see all 97 claims and to verify the 7 references still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 20
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 3. Results > 3.6. Certainty Assessment
“The GRADE evidence summary of certainty showed that all five outcomes were rated as low (abdominal pain, bloating, stool consistency, adverse events, and the number of fecal Bifidobacteria and Lactobacilli) or very low (QoL).”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 3. Results > 3.6. Certainty Assessment
“Specifically, all outcome indicators were downgraded by one level due to the limitations of those studies. Then, except for the stool consistency scores, all other outcome indicators were downgraded by one level in terms of inconsistency. Ultimately, the imprecision of the stool consistency scores, QoL scores, adverse events, and the number of fecal Bifidobacteria and Lactobacilli were all downgraded by one level (Table 2).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 2. Methods > 2.5. Data Synthesis and Statistical Analysis
“Finally, funnel plots were generated to detect publication bias.”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 3. Results > 3.5. Publication Bias
“All outcomes were constrained by the number of studies (n < 10), so we did not adopt publication bias detection.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“After reviewing the full texts, 256 reports were excluded due to the subjects not matching (diarrhea-type IBS or unclassified, n = 75); irrelevant interventions, which were a no-control or a conventional control group (n = 8); probiotics combined with herbal or other drug interventions (n = 82); irrelevant study design (n = 22); irrelevant results, which did not meet our inclusion criteria (n = 14), or incomplete data (n = 45).”
§ Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials > 3. Results > 3.1. Selection Results for the Included Studies
Reported 256 · recomputed 246
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Ji, 2022, Correlation between Intestinal Microflora in Irritable Bowel Syndrome and Severity, Dis. Markers, 2022, 1031844, 10.1155/2022/1031844”
Cited work 10.1155/2022/1031844 · retracted 2023-07-19 · notice 10.1155/2023/9818734 · this paper published 2022-06-15
Citations
Cites
1 retracted
Correlation between Intestinal Microflora in Irritable Bowel Syndrome and Severity
Ji, M., Huang, H., & Lan, X. (2022) · Disease Markers · doi:10.1155/2022/1031844 · Cited by 13
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Self-citationGRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592 · cited 1×
“When properly ingested, probiotics are living microorganisms that have potential health benefits [23,24].”
BackgroundGRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Norderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV
Drossman, D. A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.032 · Cited by 2,430
Research works printed but not linked: 3
- Hu, 2012, The changes and significances of intestinal microflora in patients with irritable bowel syndrome, Acta Univ. Med. Anhui, 47, 86
- Jang, 2012, Therapeutic efficacy of probiotics and analysis of intestinal flora in patients with irritable bowel syndrome, Chin. J. Clin. Healthc., 15, 132
- Thompson, 1989, Irritable bowel syndrome: Guidelines for the diagnosis, Gastroenterol. Int., 2, 92
Cited by
Kunugi, H. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13551 · Cited by 137
Napolitano, M., Fasulo, E., Ungaro, F., Massimino, L., Sinagra, E., Danese, S., & Mandarino, F. V. (2023) · Microorganisms · doi:10.3390/microorganisms11102369 · Cited by 107
“A meta-analysis of 10 studies, involving a total of 757 patients, evaluated the role of probiotics for IBS-C and found significantly improved stool consistency and increased fecal Bifidobacterium and Lactobacillus levels compared to the placebo [146].”
Gut microbiota and irritable bowel syndrome: status and prospect
Cheng, X., Ren, C., Mei, X., Jiang, Y., & Zhou, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1429133 · Cited by 52
So, D., Quigley, E. M. M., & Whelan, K. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000902 · Cited by 44
Chen, M., Lu, Y., Xie, C.-R., Wang, X., Feng, S., Xiao, X.-Y., & Zheng, H. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000658 · Cited by 40
“…meta-analysis included a larger number of studies than the previous and recent systematic reviews that assessed the ef fi cacy of probiotics for IBS [6,7] because we used the transformation between odds ratios and SMDs, which has been suggested and reported in the Cochrane handbook [16] and…”
Method
Metadata
- Authors
- Shang, X., E, F.-F., Guo, K.-L., Li, Y.-F., Zhao, H.-L., Wang, Y., Chen, N., Nian, T., Yang, C.-Q., Yang, K.-H., & Li, X.-X.
- Affiliations
- Lanzhou University (CN)
- Health Technology Assessment Center, Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, China
- Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
- Institute of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou 730000, China
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-06-15
- Volume
- 14
- Issue
- 12
- Pages
- 2482
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC9231226
- OpenAlex
- W4283034610
- Cited by
- 41
- References
- 67
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (72074103, 20CX9ZA109, lzujbky-2021-ct06, lzujbky-2021-kb22)
- Gansu Special Project of Soft Science (72074103, 20CX9ZA109, lzujbky-2021-ct06, lzujbky-2021-kb22)
- Fundamental Research Funds for the Central Universities (72074103, 20CX9ZA109, lzujbky-2021-ct06, lzujbky-2021-kb22)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, irritable bowel syndrome with constipation, stool consistency, abdominal pain, bloating, quality of life, adverse events, probiotic safety
- MeSH terms
- Bifidobacterium, Constipation, Flatulence, Humans, Lactobacillus, Abdominal Pain, Randomized Controlled Trials as Topic, Treatment Outcome, Probiotics, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. https://app.cochat.ai/papers/10.3390/nu14122482
- The paper
- Shang, X., E, F.-F., Guo, K.-L., Li, Y.-F., Zhao, H.-L., Wang, Y., Chen, N., Nian, T., Yang, C.-Q., Yang, K.-H., & Li, X.-X. (2022). Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. Nutrients. https://doi.org/10.3390/nu14122482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.